Skip to main content
TipRanks
Go Ultimate75% OFF

IXICO plc (PYPB) AI Stock Analysis

1 Followers
DE:PYPB

IXICO plc

(Frankfurt:PYPB)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue Growth and Order VisibilityStrong H1 growth and an order book covering most of annual guidance provide unusually clear near-term revenue visibility. The 1.75 book-to-bill ratio and rising contracted work support continued commercial momentum, helping management plan delivery and investment with greater confidence.
Negative Factors
Persistent Operating LossesDespite improvement, the business is still loss-making and management does not expect sustainable profitability until 2029. Continued investment in TechBio may prolong earnings pressure, requiring revenue growth and execution to remain strong before the operating model can produce durable profits.

IXICO plc (PYPB) vs. iShares MSCI Germany ETF (EWG)

-60%-40%-20%0%20%40%60%DE:PYPB+21.85%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 27.92M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-6.5
Beta (1Y)
-0.05
Revenue Growth
9.93%
EPS Growth
18.12%
Country
Germany
Employees
79
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

IXICO plc Business Overview & Revenue Model

Company Description

IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and in...

IXICO plc Earnings Call Summary

Earnings Call Date:May 19, 2026(Q2-2026)|% Change Since:119.70%|Next Earnings Date:Dec 08, 2026
Earnings Call SentimentPositive

The call conveyed solid operational progress and strong commercial momentum: double-digit revenue growth (23% in H1), a record GBP 18.1m order book providing 95% coverage of FY26 guidance, improved gross margin (53%), a narrowed EBITDA loss (GBP 0.5m), a successful GBP 10m capital raise and a strategic Medidata partnership that supports productization and scaling. Offsetting these positives are continuing near-term losses, timing risk for TechBio-derived recurring revenue due to productization and regulatory timelines, some exposure to trial descopes/cancellations and the need to convert an increasingly promising pipeline into contracted revenue in large indications like Alzheimer’s and Parkinson’s. Overall, the momentum and balance sheet reinforcement from the capital raise materially outweigh the near-term investment-driven drawbacks, but investors should note the multi-year horizon to realize TechBio recurring revenue and the stated 2029 target for sustained profitability.

Positive Updates

Strong Revenue Growth
Revenue for H1 FY26 was GBP 3.9m, a 23% increase versus H1 FY25, ahead of the company's 15% full-year growth guidance.

Negative Updates

Ongoing Net Losses and Near-Term EBITDA Impact
Despite narrowed losses, the business remained EBITDA negative (GBP 0.5m loss in H1). Management expects further short-term EBITDA impact due to continued TechBio investments and has pushed sustainable profitability target to 2029.

Company Guidance

The company reiterated full‑year revenue guidance of GBP 7.5m (15% growth target) after a strong H1: revenues of GBP 3.9m (+23% YoY), 53% gross margin and an EBITDA loss narrowed to GBP 0.5m; management said the record order book of GBP 18.1m (up 31% since year‑end and 38% vs H1 2025) provides ~95% visibility of this year’s guidance. Over the last 12 months IXICO recognized GBP 7.2m of revenue, signed GBP 12.6m of new contracts (book‑to‑bill 1.75) and now has its largest project at 19% of order book; cash at half‑year was GBP 1.7m, augmented by GBP 9.4m net raise to GBP 10.8m at end‑April, with net assets GBP 10.7m (long‑term assets ~GBP 8m, working capital ~GBP 3.3m, lease liabilities ~GBP 0.5m). Management expects sustainable profitability and positive cash flow by 2029, will keep capex at c. GBP 300k per half (plus recent ~GBP 100k IT and ~GBP 100k refurb), aims to productize 2–3 TechBio products this year and targets FDA/software‑as‑medical‑device regulatory work on a 18–24 month horizon.

IXICO plc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:PYPB against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:HVOGB:HVO49NeutralGBP 34.76M-2.81-35.13%3.96%-24.24%-329.49%
GB:APTAGB:APTA46NeutralGBP 12.66M-12.17-46.61%―28.35%57.14%
GB:PYCGB:PYC42NeutralGBP 1.99M-2.13-152.03%―20.05%-11.11%
GB:AVCTGB:AVCT40UnderperformGBP 287.20M-6.47-1293.07%―――
GB:OBDGB:OBD40UnderperformGBP 15.46M-0.29-451.74%―33.37%86.41%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:PYPBGB:AVCTGB:OBDGB:PYCGB:HVOGB:APTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:PYPB and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:PYPBIXICO plc0.140.0327.19%
GB:AVCTAvacta Group plc59.00-22.00-27.16%
GB:OBDOxford BioDynamics0.12-0.17-58.93%
GB:PYCPhysiomics plc0.420.011.19%
GB:HVOOpen Orphan Plc5.05-1.25-19.84%
GB:APTAAptamer Group Plc0.36-0.57-60.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.